Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements

doi:10.1038/s41698-022-00264-w

	Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
	Zhang, Yongchang 1,2; Huang, Zhe 1,2; Zeng, Liang 1; Zhang, Xiangyu 1; Li, Yizhi 1; Xu, Qinqin 3; Yang, Haiyan 1; Lizaso, Analyn 4; Xu, Chunwei 5; Liu, Jun 6
刊名	NPJ PRECISION ONCOLOGY
	2022-03-31
卷号	6
DOI	10.1038/s41698-022-00264-w
通讯作者	Zhang, Yongchang(zhangyongchang@csu.edu.cn) ; Yang, Nong(yangnong0217@163.com)
英文摘要	This retrospective study investigated the association between the pattern of disease progression and molecular mechanism of acquired resistance in a large cohort of 49 patients with ROS1-rearranged advanced non-small-cell lung cancer treated with first-line crizotinib. We found that treatment-emergent ROS1 point mutations were the major molecular mechanism of crizotinib resistance, particularly for patients who developed extracranial-only disease progression. Our findings highlight the importance of rebiopsy and gene testing for subsequent-line therapeutic management.
资助项目	Natural Science Foundation of Hunan Province[2020SK2031] ; Natural Science Foundation of Hunan Province[kq1801102] ; Natural Science Foundation of Hunan Province[2020SK2030] ; Natural Science Foundation of Hunan Province[2018RS3106] ; Natural Science Foundation of Hunan Province[2019-TJ-N04] ; Natural Science Foundation of Hunan Province[2019SK4010] ; Natural Science Foundation of Hunan Province[2020JJ3025] ; CAS Light of West China Program
WOS研究方向	Oncology
语种	英语
出版者	NATURE PORTFOLIO
WOS记录号	WOS:000776827100001
资助机构	Natural Science Foundation of Hunan Province ; CAS Light of West China Program
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/128269]
专题	中国科学院合肥物质科学研究院
通讯作者	Zhang, Yongchang; Yang, Nong
作者单位	1.Cent South Univ, Hunan Canc Hosp, Dept Med Oncol,Xiangya Sch Med, Lung Canc & Gastrointestinal Unit,Affiliated Canc, Changsha 410013, Peoples R China 2.Univ South China, Grad Collaborat Training Base, Hengyang Med Sch, Hunan Canc Hosp, Hengyang 421001, Hunan, Peoples R China 3.Qinghai Prov Peoples Hosp, Dept Med Oncol, Xining 810000, Peoples R China 4.Burning Rock Biotech, Guangzhou 510300, Peoples R China 5.Nanjing Univ, Jinling Hosp, Dept Resp Med, Sch Med, Nanjing, Peoples R China 6.Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430022, Peoples R China 7.Univ Chinese Acad Sci, Dept Med Oncol, Canc Hosp, Zhejiang Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 8.Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Dept Med, Div Hematol Oncol,Sch Med, Orange, CA USA
推荐引用方式 GB/T 7714	Zhang, Yongchang,Huang, Zhe,Zeng, Liang,et al. Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements[J]. NPJ PRECISION ONCOLOGY,2022,6.
APA	Zhang, Yongchang.,Huang, Zhe.,Zeng, Liang.,Zhang, Xiangyu.,Li, Yizhi.,...&Yang, Nong.(2022).Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements.NPJ PRECISION ONCOLOGY,6.
MLA	Zhang, Yongchang,et al."Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements".NPJ PRECISION ONCOLOGY 6(2022).